Jasper Therapeutics (NASDAQ:JSPR) Announces Quarterly Earnings Results

Jasper Therapeutics (NASDAQ:JSPR) posted its quarterly earnings data on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.47, FiscalAI reports.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR traded down $0.15 during trading on Monday, reaching $0.90. The company’s stock had a trading volume of 836,334 shares, compared to its average volume of 598,227. Jasper Therapeutics has a 12 month low of $0.88 and a 12 month high of $7.19. The firm has a market cap of $25.18 million, a price-to-earnings ratio of -0.15 and a beta of 3.08. The firm has a 50 day moving average of $1.34 and a 200-day moving average of $1.79.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in JSPR. Knott David M Jr grew its position in Jasper Therapeutics by 5.8% during the fourth quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after buying an additional 10,000 shares during the period. Acadian Asset Management LLC purchased a new position in Jasper Therapeutics in the first quarter valued at about $46,000. Engineers Gate Manager LP purchased a new position in Jasper Therapeutics in the second quarter valued at about $78,000. Renaissance Technologies LLC grew its position in shares of Jasper Therapeutics by 9.0% during the 4th quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after acquiring an additional 18,683 shares during the period. Finally, Panagora Asset Management Inc. purchased a new stake in shares of Jasper Therapeutics during the 4th quarter worth approximately $35,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JSPR has been the subject of several analyst reports. Rodman & Renshaw initiated coverage on shares of Jasper Therapeutics in a report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd. Finally, UBS Group assumed coverage on shares of Jasper Therapeutics in a research note on Monday, March 23rd. They issued a “neutral” rating for the company. Six analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Jasper Therapeutics has a consensus rating of “Hold” and a consensus price target of $19.88.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.